Blood Screening Market - Global Market Research 2015-2019
About blood screening
Blood screening is a medical process where blood is scanned for testing of particular condition or disease. This procedure is commonly performed for HIV, pregnancy, cancer, and other screening. It provides vital information to the physician regarding the functioning of organs such as kidney, liver, and thyroid. The major blood tests that are extensively used for diagnosing diseases include erythrocyte sedimentation rate (ESR), full blood count (FBC), electrolyte test, karyotyping, enzyme-linked immunosorbent assay (ELISA), C-reactive protein, liver function test, and blood cholesterol test. The market for blood screening has witnessed numerous technological advances such as shift toward the first-generation ELISA to highly advanced NAAT testing, since its inception.
Technavio's analysts forecast the global blood screening market to grow at a CAGR of 9.31% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global blood screening market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of instruments, assays/consumables, and services for the technologies such as NAAT and multiplexed real-time PCR
Technavio's report, Global Blood Screening Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, Latin America, MEA, and North America; it also covers the landscape of the global blood screening market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Blood Screening Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Blood Screening Market: Abbott Diagnostics, bioMérieux, Grifols and Roche Diagnostics
Other Prominent Vendors in the market are: Alere, Bio-Rad Laboratories, BD, Beckman Coulter, Cepheid, Diamedix, DiaSorin, Elitech, Eiken Chemical, Enzo Biochem, Fujirebio/Innogenetics, Hologic, Immunetics, Meridian Bioscience, Lab21, OraSure, Ortho Clinical Diagnostics, Qiagen, SeraCare, Siemens Healthcare Diagnostics, Thermo Fisher Scientific, and Trinity Biotech.
Commenting on the report, an analyst from Technavio’s team said: “Researchers use advanced and sophisticated tools and software to manage huge volumes of blood samples and large megabytes of data for each sample. The electronic record systems help medical experts gain access to blood samples and study their genotypic and phenotypic information. For instance, Illumina and Affymetrix provide high-throughput single-nucleotide polymorphism genotyping systems for accessing and storing genotyped data. Similarly, the barcoding system and robust encryption algorithm help in the rapid identification and increase the safety of samples.”
According to the report, blood safety is an important parameter taken into consideration after blood donation and before transfusion. The spread of infectious diseases through contaminated blood transfusions has mandated many regulatory bodies worldwide to implement stringent measures for blood screening.
Further, the report states that the technical expertise of medical professionals using these devices is not up to par, which results in operational and technological issues. These factors, though, have increased the demand for skilled medical professionals, they impede the adoption of technologically advanced diagnostic devices.
Abbott Diagnostics, bioMérieux, Grifols, Roche Diagnostics, Alere, Bio-Rad Laboratories, BD, Beckman Coulter, Cepheid, Diamedix, DiaSorin, Elitech, Eiken Chemical, Enzo Biochem, Fujirebio/Innogenetics, Hologic, Immunetics, Meridian Bioscience, Lab21, OraSure, Ortho Clinical Diagnostics, Qiagen, SeraCare, Siemens Healthcare Diagnostics, Thermo Fisher Scientific, Trinity Biotech.